Early viral-specific T-cell testing predicts late cytomegalovirus reactivation following liver transplantation.
Siddharth SoodC HaiferL YuJ PavlovicP J GowR M JonesK VisvanathanP W AngusA G TestroPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2018)
Although only 5% of recipients developed late CMV, 2/3 suffered CMV disease. M6 QFN-CMV has an excellent NPV for late CMV, suggesting patients who exhibit a robust ex vivo immune response at M6 can safely cease CMV monitoring. Furthermore, >90% already express viral-specific immunity as early as 3 months. Conceivably, antiviral prophylaxis could be discontinued early in these patients.